SNMMI calls on CMS to cover PET agent Amyvid

02/3/2013 | DOTMed.com

SNMMI and other supporters of the PET imaging agent Amyvid are calling on CMS to provide coverage of the agent for diagnosis of Alzheimer's disease. The move follows a Medicare Evidence Development and Coverage Advisory Committee hearing where the panel questioned the utility of Amyvid in improving health outcomes. SNMMI said clinical evidence and FDA approval of the agent back "the ability of beta-amyloid imaging to change patient management, leading to better outcomes for patients."

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX